Pfizer Inc.
METABOLITES OF GLP1R AGONISTS
Last updated:
Abstract:
The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
Status:
Application
Type:
Utility
Filling date:
9 Dec 2021
Issue date:
23 Jun 2022